Regeneron: A Downgrade With a Positive Bias?
August 31, 2015 at 10:08 AM EDT
Why did Chardan’s Gbola Amusa cut Regeneron Pharmaceuticals (REGN) to Neutral from Buy? If you guessed valuation, then give yourself a prize: mike segar/Reuters We downgrade Regeneron shares from Buy to Neutral on valuation. With the stock at 95% of our price target of $565, and with our view in recent months to be more selective […]
